Pharmaceuticals News and Research

RSS

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.

6 Jun 2013

Winners of EFIC-Grünenthal-Grant announced

For the 8th time the European Federation of IASP Chapters in cooperation with the pharmaceutical company Grünenthal Group announced the EFIC-Grünenthal-Grant (E-G-G) - a grant aimed to support young scientists at an early stage of their experimental projects on clinical and human volunteer-based pain research.

6 Jun 2013

New survey data reveal need for specialist nurse support in management of patients with heart failure

One year after the publication of the European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012, awareness amongst UK healthcare professionals varies dramatically.

6 Jun 2013

Health care issues take Capitol Hill stage

Representatives from both sides of the aisle focused on various issues including "dual eligibles," veterans' health care, drug-tracking laws and the U.S. Preventive Services Task Force.

6 Jun 2013

Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.

6 Jun 2013

Study suggests modulation of "enhancer-directed RNAs" can alter gene expression in living cells

In a pair of distinct but complementary papers, researchers at the University of California, San Diego School of Medicine and colleagues illuminate the functional importance of a relatively new class of RNA molecules.

5 Jun 2013

Healthcare market in Turkey to reach $29.62 billion in 2015, new analysis finds

Government funding, growth and consolidation of the middle class, and the rise in non-communicable diseases will enable Turkey to remain one of the sought-after countries for healthcare investment. Turkey offers immense potential for companies across the healthcare spectrum, from healthcare technology device suppliers to pharmaceutical and clinical diagnostic firms.

5 Jun 2013

Rubio proposes constitutional amendment to invalidate the health law's individual mandate

In other Capitol Hill action, the House approved a measure on Monday to set out how the government should track prescription drugs through the distribution chain.

5 Jun 2013

NeuroVive Pharmaceutical recruits first traumatic brain injury patient to evaluate NeuroSTAT

NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury.

5 Jun 2013

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

4 Jun 2013

Zalicus advancing Z944 into further clinical development

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it is advancing Z944, its novel oral T-type calcium channel blocker, into further clinical development in the third quarter of 2013.

4 Jun 2013

New technique selectively represses unwanted immune reactions without disabling immune system

The human immune system is remarkably efficient, but sometimes its attack is misdirected, leading to allergies, autoimmune diseases and rejection of transplant organs and therapeutic drugs. Current immune suppressants have major drawbacks, but a team from The Scripps Research Institute (TSRI) has demonstrated a new technique that may lead to a better way to selectively repress unwanted immune reactions without disabling the immune system as a whole.

4 Jun 2013

OxThera granted Japanese patents for treating oxalate-related disease

OxThera AB has been granted three Japanese patents during 2012 and 2013. The patents will secure the pharmaceutical composition and the method for treating and preventing oxalate-related disease with micro-organisms and enzymes and will further strengthen the Company's patent estate for this unmet medical need.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.

4 Jun 2013

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration.

3 Jun 2013

Arcturus Therapeutics closes $1.3 M in seed funding round

Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada.

3 Jun 2013

NewLink Genetics announces results from two clinical studies with indoximod

NewLink Genetics Corporation, an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.

3 Jun 2013

Pharmaceuticals News and Research

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

Winners of EFIC-Grünenthal-Grant announced

New survey data reveal need for specialist nurse support in management of patients with heart failure

Health care issues take Capitol Hill stage

Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder

Study suggests modulation of "enhancer-directed RNAs" can alter gene expression in living cells

Healthcare market in Turkey to reach $29.62 billion in 2015, new analysis finds

Rubio proposes constitutional amendment to invalidate the health law's individual mandate

NeuroVive Pharmaceutical recruits first traumatic brain injury patient to evaluate NeuroSTAT

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Zalicus advancing Z944 into further clinical development

New technique selectively represses unwanted immune reactions without disabling immune system

OxThera granted Japanese patents for treating oxalate-related disease

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Arcturus Therapeutics closes $1.3 M in seed funding round

NewLink Genetics announces results from two clinical studies with indoximod

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence